These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9486923)

  • 1. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin.
    Schlegel PG; Haber HP; Beck J; Krümpelmann S; Handgretinger R; Bader P; Bierings M; Niethammer D; Klingebiel T
    Ann Hematol; 1998 Jan; 76(1):37-41. PubMed ID: 9486923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
    Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
    J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of low-dose heparin and prostaglandin E1 in the prevention of hepatic veno-occlusive disease after allogenic hematopoietic stem cell transplantation in children with beta-thalassemia major].
    Sun X; Hao WG; Liu S; Xia T; Liao C
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):343-6. PubMed ID: 17706036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
    Higashigawa M; Watanabe M; Nishihara H; Tabata N; Azuma E; Ido M; Ito M; Sakurai M
    Leuk Res; 1995 Jul; 19(7):477-80. PubMed ID: 7637394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation.
    Park JE; Choi YH; Cheon JE; Kim WS; Kim IO; Ryu YJ; Kim YJ; Hong CR; Kang HJ
    Eur Radiol; 2018 Jun; 28(6):2291-2298. PubMed ID: 29294155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
    Chen J; Zhu KE; Zhang T; Zhong J; Chen ST; Zeng HL
    Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):140-2. PubMed ID: 17445443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of hepatic veno-occlusive disease by a combination of heparin and prostaglandin E1 in children undergoing hematopoietic stem cell transplantation].
    Inukai T; Sugita K; Goi K; Akahane K; Hirose K; Nemoto A; Takahashi K; Sato H; Uno K; Furuichi Y; Nakamura M; Miyamoto N; Yamakawa N; Shiraishi K; Kojika S; Tezuka T; Iijima K; Nakazawa S
    Rinsho Ketsueki; 2004 Apr; 45(4):297-303. PubMed ID: 15168445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
    Bone Marrow Transplant; 2021 Jul; 56(7):1603-1613. PubMed ID: 33526915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
    Sonneveld P; Laméris JS; Cornelissen J; Ogilvie A; Löwenberg B
    Bone Marrow Transplant; 1998 Apr; 21(7):731-4. PubMed ID: 9578316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
    Lee SH; Yoo KH; Sung KW; Koo HH; Kwon YJ; Kwon MM; Park HJ; Park BK; Kim YY; Park JA; Im HJ; Seo JJ; Kang HJ; Shin HY; Ahn HS
    Bone Marrow Transplant; 2010 Aug; 45(8):1287-93. PubMed ID: 20010866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Esperou H; Lehn P; Faure P; Drouet L
    Br J Haematol; 1990 Mar; 74(3):277-81. PubMed ID: 2159315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylaxis of hepatic veno-occlusive disease by low-molecular-weight heparin and lipo- prostaglandin E1 after allogeneic peripheral blood stem cell transplantation].
    Song CY; Li YH; Guo KY; Wu BY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):494, 497. PubMed ID: 12754143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
    Dong M; Lin Q; Wu XY
    Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Espérou H; Lehn P; Faure P; Drouet L
    Nouv Rev Fr Hematol (1978); 1990; 32(1):1-3. PubMed ID: 2349075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population?
    Szmit Z; Gorczyńska E; Mielcarek-Siedziuk M; Ussowicz M; Owoc-Lempach J; Kałwak K
    Adv Clin Exp Med; 2020 Mar; 29(3):339-344. PubMed ID: 32207590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.